

# LSP Life Sciences Fund

LSP  
CONNECTING INVESTORS TO INVENTORS

Monthly Report June 2016

NAV per Share

€ 170,17

## Performance

YTD	1 Month	3 Months	1 Year	2 Years	3 Years
-19,7%	-11,5%	6,5%	-20,6%	6,2%	37,9%

NAV of Fund 75.565.582

Number of Shares 444.041

Valuation Date 30-6-2016

## Top-5 performers

1. Clinigen Group	9,0%
2. GW Pharmaceuticals	2,7%
3. Genmab	0,2%
4. ProQR Therapeutics	-0,4%
5. Kite Pharma	-2,4%

Inception date: 27-4-2011

Currency: Euro

Domicile: The Netherlands

Legal Structure: Dutch NV with variable capital

Listing: Euronext Amsterdam

Euronext code: LSP

ISIN Code: NL0009756394

Bloomberg: LSP NA


## Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 2.5 billion at the time of investment.

## Manager's comments

The month of June was characterized by significant market volatility attributable to the referendum held in the UK on whether or not to stay in the EU. Following a strong start of the month, polls started to indicate that the "leave vote" may actually win by a thin margin, which led to a change in sentiment and – as a result – investors selling equities across the board. Many investors left the biopharmaceutical sector, since it is perceived as higher risk. As we have seen many times over the past years, in times of uncertainty, the sector loses much of its attraction and vice-versa when the uncertainty diminishes. Given the nature of the LSP Fund - long only and fundamental bottom up, deep-analytical stock picking strategy leading to a highly concentrated portfolio of true conviction investments – one cannot exclude volatility resulting from external events such as Brexit. We have not forgotten the increased uncertainties around China's growth, the world's oil supply, FED's interest rate policy, the Eurocrisis and many more macro-economic and political events that have taken place in the recent past, all of which had a negative impact on global sentiment, on the overall equity markets and on investor's risk appetite. These are all a fact of (investor's) life. The fund cannot and will not play these themes in any way. It only looks to invest in companies that it believes are fundamentally sound, offer significant upside and are - typically – undervalued. The future value of the portfolio will be driven by the growth potential of the underlying companies that – in turn – are driven by the advancements made of their products and technologies. Looking back at the past month and past quarter, the various portfolio companies have come out with overwhelmingly good news and are developing exactly in line with the underlying investment cases. Irrespective of increased uncertainty due to Brexit and other factors – positive news flow from medical and scientific breakthroughs will define the sector.

## Portfolio breakdown



## Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via [www.lspvc.com/funds/public.html](http://www.lspvc.com/funds/public.html)

## Portfolio breakdown

Company	Stage	Subsector	Marketcap	%
GW Pharmaceuticals	Market	Therapeutics	Mid	8,3%
Galapagos	Late	Therapeutics	Mid	7,4%
Cempra	Late	Therapeutics	Small	7,3%
Genmab	Market	Therapeutics	Mid	7,0%
Neuroderm	Early	Therapeutics	Small	6,7%
Ablynx	Early	Therapeutics	Small	6,4%
Forward Pharma	Late	Therapeutics	Small	6,1%
Spark Therapeutics	Late	Therapeutics	Mid	5,6%
Neurocrine Biosciences	Late	Therapeutics	Mid	5,3%
Morphosys	Late	Therapeutics	Mid	4,9%
Ophthotech	Late	Therapeutics	Mid	4,9%
Evotec	Early	Therapeutics	Small	4,8%
Clinigen Group	Market	Specialty Pharma	Small	4,3%
Kite Pharma	Early	Therapeutics	Mid	3,9%
Juno Therapeutics	Early	Therapeutics	Mid	3,7%
ProQR Therapeutics	Early	Therapeutics	Small	2,0%
Sphere Medical	Market	Medical Device	Micro	1,6%
Lombard Medical	Market	Medical Device	Micro	1,0%